id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-012618-ulqajban	Jiang, Hai	The expanding vulnerabilities of being UTXless	2019-04-26		.txt	text/plain	1093	69	47	1 published in Signal Transduction and Targeted Therapy, Dr. Yu Liu and collaborators report that the differentiation block in UTX-null leukemia cells can be reverted by an LSD1 inhibitor, highlighting additional ways of targeting UTX-deficient malignancies. 2 A series of recent studies have established the role of UTX as a tumor suppressor in leukemia, lymphoma, pancreatic, and lung cancers. In many cancer models, the role of UTX as a tumor suppressor has been linked to epigenetic changes associated with UTX loss. 6, 9 Second, in pancreatic cancer models it was found that UTX-deficient cancer is sensitive to BET inhibitors, which restrain gene expression from super-enhancers that are altered by UTX loss. In AML, the loss of the H3K27 methyltransferase EZH2 induced resistance to cytarabine, 10 whereas in lymphoma models the loss of the H3K27 demethylase UTX sensitized the cells to this drug. Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy	./cache/cord-012618-ulqajban.txt	./txt/cord-012618-ulqajban.txt